Background: Alzheimer’s disease (AD) research has long been dominated by the amyloid cascade hypothesis, yet the persistent failure of amyloid-targeting therapies suggests that other early-stage pathological drivers remain under-addressed. A growing body of evidence indicates that astrocyte-specific metabolic dysfunction is a primary, rather than secondary, event in AD progression. As the central metabolic hubs of the brain, astrocytes are responsible for the astrocyte-neuron lactate shuttle (ANLS), providing the energetic substrate (lactate) necessary for neuronal synaptic plasticity and memory formation.
Methods: To investigate these glial contributions, we have utilized patient-derived induced neural progenitor cells (iNPCs). By differentiating these cells into mature astrocytes, we can model the disease using the unique genetic and aging signatures of both sporadic (sAD) and familial (fAD) patients. These models allow for the precise measurement of mitochondrial respiration, glycolytic flux, and the transport of metabolites between glial and neuronal populations.
Key Findings: Current research into the glial-metabolic interface has yielded several critical insights:
-
Bioenergetic failure: Astrocytes derived from AD patients exhibit a “hypometabolic” state characterized by significantly reduced basal respiration and spare respiratory capacity. This suggests an inability to scale energy production during periods of high neuronal activity.
-
Glycolytic Impairment and Hexokinase 1 (HK1): A specific deficiency in Hexokinase 1, the enzyme responsible for the first step of glucose metabolism, has been identified in sAD astrocytes. The displacement of HK1 from the mitochondria disrupts the coupling of glycolysis and oxidative phosphorylation, leading to a “starved” cellular environment.
-
Lactate Deprivation: Because AD astrocytes fail to maintain high rates of glycolysis, they export significantly less lactate to the extracellular space. This deprivation has potential to leave neurons energetically vulnerable, directly contributing to the loss of long-term potentiation (LTP) and the eventual death of synapses.
-
Mitochondrial Morphology: AD-affected astrocytes show increased mitochondrial fragmentation, which correlates with higher levels of oxidative stress and has potential to lead to reduced calcium buffering, further destabilizing the neural microenvironment.
Clinical Significance: We have also shown a correlation between the metabolic health of these patient-derived astrocytes and the donor’s actual cognitive performance. Specifically, higher levels of astrocytic glycolytic reserve in vitro are predictive of better episodic memory scores in vivo. This underscores the potential of astrocytic health as a viable biomarker for disease progression.
Conclusion: Astrocyte metabolic “exhaustion” may be a critical checkpoint in neurodegeneration. Restoring the metabolic link between astrocytes and neurons—specifically by targeting HK1 or augmenting lactate availability—represents a promising therapeutic frontier. By stabilizing the brain’s “support system,” it may be possible to preserve cognitive function even in the presence of proteinopathy.